BA
DXCM icon

Bard Associates’s DexCom DXCM Stock Holding History

Bard Associates’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.47K Buy
+96
New +$6.4K ﹤0.01% 247

Other funds holding DXCM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bard Associates's DXCM Position: Q2 2026 in Review

Bard Associates opened a new position in DexCom (DXCM) in Q2 2026: 96 shares worth $6.47K. The stake represents ﹤0.01% of the portfolio and ranks #247 among its holdings.

968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Bard Associates held 96 shares of DexCom worth $6.47K as of Q2 2026.
  • DexCom was a new Bard Associates position in Q2 2026.
  • DexCom made up ﹤0.01% of Bard Associates's portfolio in Q2 2026, its #247 holding.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Bard Associates's 13F filing for Q2 2026, filed 12 Aug 2026.